Antagonists of B2 bradykinin receptors.
Bradykinin and its active metabolites, produced by kallikreins at their sites of action, potently elicit a variety of biological effects: hypotension, bronchoconstriction, gut and uterine contraction, epithelial secretion in airway, gut, and exocrine glands, vascular permeability, pain, connective tissue proliferation, cytokine release, and eicosanoid formation. These effects are mediated by at least two broad classes of receptors. The most common is the B2 subtype. The availability of competitive antagonists of B2 receptors has provided powerful tools for the study of bradykinin's actions. The significance of kinins in certain human diseases is being explored by using these agents as potential therapeutic agents. Human clinical trials are under way to test the usefulness of bradykinin receptor antagonists to treat symptoms of the common cold and the pain associated with severe burns. Trials are also being comtemplated for use in treatment of asthma.
Steranka
L R
LR
Nova Pharmaceutical Corporation, Baltimore, Maryland 21224.
Farmer
S G
SG
Burch
R M
RM
D000403:Airway Resistance; D000818:Animals; D001920:Bradykinin / Q000037:antagonists & inhibitors*; D006439:Hemodynamics; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D018002:Receptors, Bradykinin; D017981:Receptors, Neurotransmitter / Q000145:classification / Q000187:drug effects*; D012772:Shock, Septic / Q000503:physiopathology; D013329:Structure-Activity Relationship
D018002:Receptors, Bradykinin; D017981:Receptors, Neurotransmitter; D001920:Bradykinin